Minimally invasive nipple-sparing mastectomy: fewer complications, longer operations, unproven oncology

Design

Systematic review and meta-analysis of 12 comparative studies

Population

Patients undergoing nipple-areola complex-sparing mastectomy for breast cancer, robotic or endoscopic versus open

Primary outcome

Perioperative outcomes, postoperative complications, aesthetic-related outcomes and recurrence

Effect

Minimally invasive approach: longer operative time; less blood loss, shorter incisions, shorter reconstruction time; lower overall complications, skin necrosis, seroma and haematoma. No difference in delayed wound healing, nipple-areola complications, nipple or flap necrosis, or recurrence

Robotic and endoscopic approaches to nipple-sparing mastectomy have spread faster than the evidence behind them. This meta-analysis pooled 12 studies comparing minimally invasive with conventional open nipple-sparing mastectomy.

The perioperative picture favours the minimally invasive approach on most measures: less blood loss, shorter incisions, shorter reconstruction time, and lower rates of overall complications, skin necrosis, seroma and haematoma or bleeding. The trade is operating time, which was longer. Several outcomes did not differ — delayed wound healing, nipple-areola complex complications, nipple necrosis and flap necrosis among them.

Recurrence also did not differ, and that is where the caution belongs. Recurrence after breast cancer surgery is measured in years, the included studies are observational comparisons, and the authors say plainly that long-term oncological outcomes and patient-reported aesthetic benefit remain inadequately evidenced. A technique that reduces short-term complications is worth having; it is not yet established as oncologically equivalent, and the patient consenting to it should be told which of those two statements is supported.

• Discuss the perioperative advantages as demonstrated and the oncological equivalence as not yet established
• Factor the longer operating time into theatre scheduling and anaesthetic risk
• Reserve for selected patients, as the included studies did
• Record recurrence and aesthetic outcomes prospectively — that is the gap
• Note that nipple and flap necrosis rates were no different; the gain is in skin necrosis, seroma and bleeding

Why it matters

The advantages that are proven and the advantage patients assume they are getting are not the same advantage.

Don't overread it

No difference in recurrence in short observational follow-up is not evidence of oncological equivalence.

The statistics, in plain English

No pooled effect sizes are reported in the available record, so the direction of each finding is all that can be stated, and this briefing will not invent magnitudes. More importantly, 'no significant difference in recurrence' across 12 observational studies with limited follow-up is a statement about power, not about equivalence: these studies were never large enough or long enough to exclude a meaningful difference.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.